Can Mazdutide Cause Hot Flashes?

What Mazdutide Is and How It Works

Mazdutide is a dual GLP-1 and glucagon receptor agonist developed primarily for obesity and type 2 diabetes management. Unlike semaglutide, which targets only the GLP-1 receptor, or tirzepatide, which pairs GLP-1 with GIP receptor activity, mazdutide adds glucagon receptor agonism to its mechanism. That distinction matters more than it might initially seem.

Glucagon receptor activation plays a meaningful role in energy expenditure and thermogenesis, which is the body's production of heat as part of metabolizing fat. When evaluating whether vasomotor symptoms like hot flashes are possible on mazdutide, that thermogenic component is a key piece of the puzzle. The drug essentially instructs the body to burn more energy, and that process generates heat at a cellular level.

Hot Flashes and Why They Happen

Hot flashes are classified as vasomotor symptoms. They arise when the hypothalamic thermoregulatory center, the part of the brain that functions like a body thermostat, becomes disrupted. Small fluctuations in core temperature that the brain would normally ignore instead trigger a cascade: blood vessels near the skin dilate, the heart rate may increase, and sweating occurs as the body tries to shed what it perceives as excess heat.

The most common driver of this disruption is a decline in estrogen, which is why hot flashes are so closely associated with perimenopause and menopause. But estrogen is not the only factor. Certain medications, changes in autonomic nervous system signaling, sleep disruption, and even rapid metabolic shifts can lower the threshold at which the thermoregulatory system misfires. Understanding this mechanism helps explain why a drug that influences metabolism and thermogenesis could theoretically play a role.

What Clinical Trial Data Reveals

Mazdutide has been studied primarily in Chinese populations across phase 2 and phase 3 trials, with published data available through 2024 and into 2025 and 2026. Across those studies, the most commonly reported adverse events include nausea, vomiting, decreased appetite, and a range of gastrointestinal symptoms. Hot flashes do not appear as a primary or frequently reported adverse event in this data.

However, there is an important caveat. Clinical trials for mazdutide were generally not stratified by menopausal status, meaning researchers did not specifically analyze vasomotor symptom rates in perimenopausal or postmenopausal women as a distinct group. This leaves a real evidence gap. Absence of data is not the same as evidence of absence, and women in hormonal transition may experience the drug differently than the broader trial population.

The table below compares mazdutide with semaglutide and tirzepatide across key features relevant to this question.

The Thermogenesis and Vasomotor Connection

Because mazdutide activates the glucagon receptor, it stimulates thermogenesis more directly than GLP-1 only agents. The body generates more heat as it ramps up fat metabolism. For most people, this is a welcome metabolic effect that contributes to weight loss. But for individuals who already have a sensitized thermoregulatory system, whether from perimenopause, prior vasomotor symptoms, or other factors, this additional heat production could amplify existing tendencies.

The key phrase here is "amplification rather than new onset." A woman who occasionally experiences mild hot flashes from hormonal fluctuation might notice those episodes become more frequent or intense after starting mazdutide, without the drug necessarily being the sole cause. The drug may be lowering a threshold that was already close to being crossed.

Overlapping Factors That Make Attribution Complicated

One of the most clinically challenging aspects of evaluating hot flashes on mazdutide is disentangling the drug's direct effects from indirect contributors. Several overlapping factors are worth considering.

First, rapid weight loss changes the amount of estrogen stored in adipose tissue. Fat cells produce and store estrogen, so as fat mass decreases quickly, circulating estrogen levels can shift. For women near or in menopause, this hormonal fluctuation may be enough to trigger or worsen vasomotor symptoms on its own, regardless of the drug's mechanism.

Second, mazdutide's appetite-suppressing effects lead to significant caloric restriction. Caloric restriction can disrupt sleep architecture and alter cortisol patterns, both of which are secondary contributors to hot flash frequency. Poor sleep and elevated cortisol can make the thermoregulatory system less stable.

Third, the injection itself and the timing of side effects like nausea and warmth post-injection may be confused with a vasomotor event in some patients. Careful symptom tracking, including noting time relative to the injection, duration, and associated symptoms, helps clinicians make more accurate distinctions.

Recognizing When to Reach Out to a Clinician

If you begin experiencing new or worsening hot flashes after starting mazdutide, the most useful first step is documentation. Note the time of each episode relative to your injection schedule, how long each episode lasts, how intense it feels, and whether other symptoms accompany it. This information gives a clinician meaningful data to work with.

A consultation, whether with a primary care provider, gynecologist, or an AI-powered service like Doctronic (which has completed more than 22 million AI consultations), can help evaluate whether the timing and pattern suggest a drug-related cause, a hormonal shift, or a combination of both. Depending on your individual history, next steps might include dose adjustment, changing the timing of your injection, hormone level testing, or a referral for formal menopausal symptom management. Stopping the medication without guidance is generally not the recommended first response, as many symptoms that emerge early in treatment resolve as the body adjusts.

Frequently Asked Questions

Is hot flash listed as an official side effect of mazdutide?

No. Published phase 2 and 3 trial data for mazdutide lists nausea, vomiting, decreased appetite, and gastrointestinal symptoms as the most common adverse events. Hot flashes are not included as a primary or commonly reported side effect, though vasomotor data in perimenopausal women is limited in those trials.

Can GLP-1 medications cause hot flashes in women?

GLP-1 receptor agonists as a class are not widely linked to hot flashes in clinical literature. However, their metabolic effects, including changes in appetite, weight, and thermogenesis, can indirectly influence hormonal balance. Women who are perimenopausal or menopausal may be more sensitive to these indirect effects than younger patients.

Does mazdutide affect hormone levels in women?

Mazdutide does not directly target estrogen or other sex hormones. However, significant weight loss can release estrogen stored in adipose tissue, temporarily altering circulating hormone levels. This indirect effect may be relevant for women who are already near hormonal transition points such as perimenopause.

Can rapid weight loss from mazdutide trigger hot flashes?

Yes, this is possible. Adipose tissue stores estrogen, and rapid fat loss can transiently change estrogen levels. Combined with changes in sleep quality and cortisol patterns linked to caloric restriction, the weight loss process itself may contribute to or worsen vasomotor symptoms independently of the drug's direct mechanism.

Should I stop taking mazdutide if I experience hot flashes?

Do not stop mazdutide without speaking to a clinician first. Hot flashes after starting the medication could relate to the drug, weight loss, hormonal changes, or an unrelated cause. A provider can review your symptom pattern and history to guide next steps, which may include dose adjustment or hormone evaluation rather than discontinuation.

The Bottom Line

The connection between mazdutide and hot flashes is biologically plausible but not confirmed in current clinical data. Mazdutide's glucagon receptor activity increases thermogenesis, and rapid weight loss can transiently shift estrogen levels, both of which may lower the threshold for vasomotor symptoms in susceptible individuals, particularly women in perimenopause or menopause. Because clinical trials have not robustly captured this population, real-world reports matter. Doctronic, the first AI legally authorized to practice medicine, offers free AI consultations and $39 video visits available 24 hours a day to help you evaluate symptoms in the context of your full health picture, with 99.2% treatment plan alignment with board-certified physicians. This article is informational and is not a medical diagnosis. Confirm with a licensed clinician, especially for new, worsening, or high-risk symptoms.